Business Context and Reporting Period
Company: Revelation Biosciences, Inc. (REVB)
Filing Type: Form 8-K (Current Report)
Date of Report: September 9, 2025
Event: Announcement of top-line results from the PRIME Phase 1b clinical study in chronic kidney disease patients.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a corporate event and does not contain audited financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material change reported is the release of positive clinical data from the PRIME Phase 1b study. No financial changes versus prior periods are disclosed in this document.
Guidance, Outlook, and Management Commentary
- Clinical Results: The Company announced "groundbreaking" and "positive" top-line results from the PRIME Phase 1b clinical study in chronic kidney disease patients.
- Public Disclosure: A corporate presentation containing the top-line data was made available to the public and is attached as Exhibit 99.2.
- Legal Status of Information: The press release and presentation are incorporated by reference but are not treated as "filed" under Section 18 of the Exchange Act for liability purposes unless expressly incorporated into future filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) and Exhibit 99.2 (Corporate Presentation) for specific clinical data points and statistical significance.
- Verify the specific endpoints met in the PRIME Phase 1b study for chronic kidney disease.
- Check subsequent filings (e.g., 10-Q or 10-K) for the financial impact of these results on the company's cash burn or funding requirements.
- Confirm the timeline for any potential Phase 2 study initiation based on these results.